The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues

The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical appl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Editorial team Diabetes Mellitus
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	empaglflozin type 2 diabetes mellitus cardiovascular disease mortality empa-reg outcome trial Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/5f7ca36e59854d25a5d206eef64bffb3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f7ca36e59854d25a5d206eef64bffb3
record_format	dspace
spelling	oai:doaj.org-article:5f7ca36e59854d25a5d206eef64bffb32021-11-14T09:00:20ZThe interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues2072-03512072-037810.14341/DM2004156-61https://doaj.org/article/5f7ca36e59854d25a5d206eef64bffb32016-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7968https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical application in patients with type 2 diabetes at high cardiovascular risk.Editorial team Diabetes MellitusEndocrinology Research Centrearticleempaglflozintype 2 diabetes mellituscardiovascular diseasemortalityempa-reg outcome trialNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 2, Pp 182-185 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	empaglflozin type 2 diabetes mellitus cardiovascular disease mortality empa-reg outcome trial Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	empaglflozin type 2 diabetes mellitus cardiovascular disease mortality empa-reg outcome trial Nutritional diseases. Deficiency diseases RC620-627 Editorial team Diabetes Mellitus The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
description	The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical application in patients with type 2 diabetes at high cardiovascular risk.
format	article
author	Editorial team Diabetes Mellitus
author_facet	Editorial team Diabetes Mellitus
author_sort	Editorial team Diabetes Mellitus
title	The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_short	The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_full	The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_fullStr	The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_full_unstemmed	The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
title_sort	interim experts’ counsil resolution on the empa-reg outcome trial issues
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/5f7ca36e59854d25a5d206eef64bffb3
work_keys_str_mv	AT editorialteamdiabetesmellitus theinterimexpertscounsilresolutionontheemparegoutcometrialissues AT editorialteamdiabetesmellitus interimexpertscounsilresolutionontheemparegoutcometrialissues
_version_	1718429530881785856

The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues

Ejemplares similares